|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2005-8-2
|
|
pubmed:abstractText |
OSI-7904L is a liposomal formulation of a potent noncompetitive thymidylate synthase inhibitor (TSI) that does not require polyglutamation for activity. This phase I study was done to establish the safety, tolerability, maximum tolerated dose, recommended dose, and pharmacokinetics of OSI-7904L in patients with advanced solid tumors refractory to standard therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5487-95
|
|
pubmed:dateRevised |
2009-2-26
|
|
pubmed:meshHeading |
pubmed-meshheading:16061865-Adult,
pubmed-meshheading:16061865-Aged,
pubmed-meshheading:16061865-Antineoplastic Agents,
pubmed-meshheading:16061865-Area Under Curve,
pubmed-meshheading:16061865-Deoxyuridine,
pubmed-meshheading:16061865-Dose-Response Relationship, Drug,
pubmed-meshheading:16061865-Enzyme Inhibitors,
pubmed-meshheading:16061865-Female,
pubmed-meshheading:16061865-Genotype,
pubmed-meshheading:16061865-Glutarates,
pubmed-meshheading:16061865-Homocysteine,
pubmed-meshheading:16061865-Humans,
pubmed-meshheading:16061865-Infusions, Intravenous,
pubmed-meshheading:16061865-Isoindoles,
pubmed-meshheading:16061865-Liposomes,
pubmed-meshheading:16061865-Male,
pubmed-meshheading:16061865-Maximum Tolerated Dose,
pubmed-meshheading:16061865-Middle Aged,
pubmed-meshheading:16061865-Neoplasms,
pubmed-meshheading:16061865-Polymorphism, Genetic,
pubmed-meshheading:16061865-Quinazolines,
pubmed-meshheading:16061865-Sepsis,
pubmed-meshheading:16061865-Thymidylate Synthase,
pubmed-meshheading:16061865-Time Factors,
pubmed-meshheading:16061865-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
|
|
pubmed:affiliation |
Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Hannover, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
